Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment

PURPOSE: The poly(ADP-ribose) polymerase inhibitor rucaparib is approved for the treatment of patients with recurrent ovarian and metastatic castration-resistant prostate cancer; however, limited data are available on its use in patients with hepatic dysfunction. This study investigated whether hepa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Chemother Pharmacol
Main Authors: Grechko, Nikolay, Skarbova, Viera, Tomaszewska-Kiecana, Monika, Ramlau, Rodryg, Centkowski, Piotr, Drew, Yvette, Dziadziuszko, Rafal, Zemanova, Milada, Beltman, Jeri, Nash, Eileen, Habeck, Jenn, Liao, Mingxiang, Xiao, Jim
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2021
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8236452/
https://ncbi.nlm.nih.gov/pubmed/33909097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-021-04278-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados